Explore the efficacy and safety of probiotics combined with mesalazine in the treatment of patients with inflammatory bowel disease based on data mining
To systematically evaluate the efficacy and risk of probiotics combined with mesalazine in the treatment of inflammatory bowel disease(IBD).CNKI,Wanfang,VIP databases,The Cochrane Library,The PubMed and Embase were searched by computer,the literatue search included articles from the estabishment of the databases to May 2023.The RevMan 5.4 software was used to conduct a statistical analysis of the correlation between the literature and data information obtained by two re-viewers who were screened independently according to the inclusion and exclusion criteria,and which had been assessed for risk of bias.A total of 26 randomized controlled trials including 2707 patients with inflammatory bowel disease were included.Meta-analysis results showed that probiotics combined with mesalamine could significantly improve the total effective rate(OR=4.45,95％CI:3.50～5.66,P＜0.000 01),and reduce the inflammatory mediators TNF-α(SMD=-1.90,95％CI:-2.91～-0.90,P=0.000 2),IL-8(SMD=-1.60,95％CI:-2.04～-1.16,P＜0.000 01),increased immune factor IL-10(SMD=1.79,95％CI:0.47～3.10,P=0.008).At the same time,the combi-nation therapy can better improve the patient's immune function and enhance the intestinal mucosal barrier.Probiotics combined with mesalazine can significantly control inflammation,enhance human immunity,and improve intestinal mucosa,which is an effective method for the treatment of IBD.
万方数据
维普
